section name header

Information

  1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664.
  2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61-66.
  3. Lacroix M. Significance, detection, and markers of disseminated breast cancer cells. Endocr Relat Cancer. 2006;13:1033-1067.
  4. Chiang AC, Massague JM. Molecular basis of metastasis. N Engl J Med. 2008;359(26): 2814-2823.
  5. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(30):692-696.
  6. Yeung RS. The osteoprotegerin/osteoprotegerin ligand family: Role in inflammation and bone loss. J Rheumatol 2004;31(5):844-846.
  7. Eli Lilly and Co. http://www.lilly.com/news/pdf/bone_remodeling_process_1003.pdf
  8. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
  9. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 1991;51:3059-3061.
  10. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000;10:159-178.
  11. Chattopadhyay N. Effects of calcium-sensing receptor on the secretion of parathyroid hormone-related peptide and its impact on humoral hypercalcemia of malignancy. Am J Physiol Endocrinol Metab. 2006;290:E761-E770.
  12. Bu G, Lu W, Liu CC, et al. Breast cancer derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implications for breast cancer osteolytic bone metastases. Int J Cancer. 2008;123(5):1034-1042.
  13. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20 suppl):6213s-6216s.
  14. Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis. 2002;5:264-272.
  15. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96:671-675.
  16. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106(7):2472-2483.
  17. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12(2):6296s-6300s.
  18. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038-2044.
  19. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-691.
  20. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;3:CD003474.
  21. Prolia. Drugs.com Web site. http://www.drugs.com/nda/denosumab_090218.html?printable=1. Accessed October 2, 2009.
  22. Schwartz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther. 2007;9(suppl 1):S1-S6.
  23. Coleman RE. Targeting the tumor microenvironment: denosumab, a new RANKL inhibitor. Breast Cancer Res. 2009;11(suppl 1):S16. Presented at VIII Madrid Breast Cancer Conference: Latest Advances in Breast Cancer. Madrid, Spain; June 24-26, 2009.
  24. Fizazi K, Bosserman L, Guozhi G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urology. 2009;182(2):509-616.
  25. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564-1571.
  26. Lonning PE. Endocrine therapy and bone loss in breast cancer: time to closing in the RANK(L)? J Clin Oncol. 2008;26(20):4859-4861.
  27. Ellis GK, Bone HG, Chllebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875-4882.
  28. Saad F, Smith MR, Smith B, et al. Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer. J Clin Oncol. 2009;27:15s. Abstract 5056.
  29. Smith MR, Ellis G, Saad T, et al. Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. J Clin Oncol. 2009;27:15s. Abstract 9520.
  30. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164.
  31. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guidelines update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;17(10):2464-2472.
  32. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-110.
  33. Ruggiero S, Gralow J, Marx RE, Engroff SL. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2(1):7-14.
  34. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 1009;76:209-211.
  35. Dental health during cancer treatment. Zometa Web site. http://www.us.zometa.com/info/cancer _bones/dental_health.jsp. Accessed October 2, 2009.
  36. American Society of Clinical Oncology (ASCO). ASCO Clinical practice guideline: The role of bisphosphonates in multiple myeloma. http://jco.ascopubs.org/cgi/content/full/20/17/3719. Accessed October 21, 2009.
  37. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis. 2008;29(6):1092-1095.
  38. DePinho RA, Polyak K. Cancer chromosome in crisis. Nat Genet. 2004;36(9):932-934.
  39. Chin K, de Solorzano CO, Knowles D, et al. In situ analyses of genome instability in breast cancer. Nat Genet. 2004;36(9):984-988.
  40. Are we “Livin” or just “Survivin”? Imgenex Web site. http://www.imgenex.com/emarketing/081606_LivinorSurvivin/LivinorSurvivin_forweb.htm. Accessed October 2, 2009.
  41. Susin SA, Daugas E, Ravaagnan L, et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med. 2000;192(4):571-580.
  42. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res. 2000;256(1):12-18.
  43. Li MO, Sarkasian MR, Mehal WZ, Rakic P, Flavell RA. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science. 2003;302(5650):1560-1563.
  44. Riedl SJ, Salvesen GS. The apoptosome: signaling platform of cell death. Nat Rev Mol Cell Biol. 2007;8:405-413.
  45. Goodsell DS. The molecular perspective: Bcl-2 and apoptosis. Oncologist. 2002;7(3):259-260.
  46. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-194.
  47. Spurgers KB, Chari NS, Bohnenstiehl NL, McDonnell TJ. Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy. Cell Death Differentiation. 2006;13:1360-1370.
  48. Ashkenazi A. Targeting death and decoy receptors of the tumor necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
  49. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006:5(5):1087-1098.
  50. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003;14(3-4):337-348.
  51. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621-3630.
  52. Jin H, Yang R, Ross J, et al. Cooperation of the agonistic DR5 antibody Apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. 2008; 14:7733-7744.
  53. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111-137.
  54. Lodish H, Berk A, Matsudaira P, et al. Molecular Biology of the Cell. 5th ed. New York, NY: WH Freeman;.2004:963.
  55. DeSoto JA, Deng C-X. PARP-1 inhibitors: are they the long-sought genetic drugs for BRCA1/2associated breast cancers? Int J Med Sci. 2006;3(4):117-123.
  56. Iglehart JD, Silver DP. Synthetic lethality—a new direction in cancer-drug development. N Engl J Med. 2009;361(2):189-191.
  57. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
  58. Virag L, Szabo C. The therapeutic potential of poly(ADP-Ribose)polymerase inhibitors. Pharm Rev. 2002;54:375-429.
  59. O'Shaughnessy J, Osborne O, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol. 2009;27(suppl; abstr 3):18s.
  60. Trivedi RN, Almeida KH, Fornsaglio JL, et al. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005;65:6394-6400.
  61. Shah MA, Schwartz GK. Cell cycle modulation: an emerging target for cancer therapy. In: Horizons in Cancer Therapeutics: From Bench to Bedside. West Conchohocken, PA: Meniscus; 2003.
  62. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev New Drug Discovery. 2009;8:547-566.
  63. Ashwell S, Zabludoff S. DNA damage detection and repair pathwasy—recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res. 2006;14(13):4032-4037.
  64. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res. 2006;12(23):6869-6875.
  65. VanderPorten EC, Taverna P, Hogan J, et al. The aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009; 8(4):930-939.